Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

CDK4/6 inhibition in breast cancer: current practice and future directions

Open access
Pernas, Sonia, Tolaney, Sara M., Winer, Eric P., Goel, Shom · 2018 · Therapeutic Advances in Medical Oncology

Abstract

The cyclin D/cyclin-dependent kinases 4 and 6 (CDK4/6)–retinoblastoma protein (RB) pathway plays a key role in the proliferation of both normal breast epithelium and breast cancer cells. A strong rationale for inhibiting CDK4/6 in breast cancers has been present for many years. However, potent and selective CDK4/6 inhibitors have only recently become available. These agents prevent phosphorylation of the RB tumor suppressor, thereby invoking cancer cell cycle arrest in G1. CDK4/6 inhibitors have transited rapidly from preclinical studies to the clinical arena, and three have already been approved for the treatment of advanced, estrogen receptor (ER)-positive breast cancer patients on account of striking clinical trial results demonstrating substantial improvements in progression-free survival. ER-positive breast cancers harbor several molecular features that would predict their sensitivity to CDK4/6 inhibitors. As physicians gain experience with using these agents in the clinic, new questions arise: are CDK4/6 inhibitors likely to be useful for patients with other subtypes of breast cancer? Are there other agents that could be effectively combined with CDK4/6 inhibitors, beyond endocrine therapy? Is there a rationale for combining CDK4/6 inhibitors with novel immune-based therapies? In this review, we describe not only the clinical data available to date, but also the biology of the CDK4/6 pathway and discuss answers to these questions. In particular, we highlight that CDK4 and CDK6 govern much more than the cancer cell cycle, and that their optimal use in the clinic depends on a deeper understanding of the less well characterized effects of these enzymes.

Overview

Integrity signals

Registry

Crossref · 10.1177/1758835918786451

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1. The role of the cyclin D1–CDK4/6–RB pathway in breast cancer. The role of the cyclin D1–CDK4/6-RB pathway in breast cancer cells, including cross talk with other oncogenic signaling pathways. Mitogenic forces including ER transcriptional activity and signaling through ERBB2/PI3K/AKT/mTOR increase cyclin D1 levels, activating CDK4/6 and promoting cellular progression to the S phase. There is extensive crosstalk between the PI3K and CDK4/6 pathways: not only does PI3K pathway activity increase cyclin D1 levels, but the cyclin D–CDK4/6 complex can modulate TSC2 phosphorylation and hence mTORC1 activity. Combined inhibition of CDK4/6 and nodes in the PI3K pathway can thus maximally suppress mTORC1 activity as well as RB phosphorylation, inhibiting two promoters of S phase progression. Furthermore, suppression of E2F activity can modulate the tumor cell epigenome, rendering tumor cells more immunogenic and providing a rationale for CDK4/6-immunotherapy combinations. AR, androgen receptor; EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide-3-kinase; RB, retinoblastoma protein, TSC2, tuberous sclerosis complex 2 (tuberin).
Figure 1. The role of the cyclin D1–CDK4/6–RB pathway in breast cancer. The role of the cyclin D1–CDK4/6-RB pathway in breast cancer cells, including cross talk with other oncogenic signaling pathways. Mitogenic forces including ER transcriptional activity and signaling through ERBB2/PI3K/AKT/mTOR increase cyclin D1 levels, activating CDK4/6 and promoting cellular progression to the S phase. There is extensive crosstalk between the PI3K and CDK4/6 pathways: not only does PI3K pathway activity increase cyclin D1 levels, but the cyclin D–CDK4/6 complex can modulate TSC2 phosphorylation and hence mTORC1 activity. Combined inhibition of CDK4/6 and nodes in the PI3K pathway can thus maximally suppress mTORC1 activity as well as RB phosphorylation, inhibiting two promoters of S phase progression. Furthermore, suppression of E2F activity can modulate the tumor cell epigenome, rendering tumor cells more immunogenic and providing a rationale for CDK4/6-immunotherapy combinations. AR, androgen receptor; EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide-3-kinase; RB, retinoblastoma protein, TSC2, tuberous sclerosis complex 2 (tuberin).CC BY-NC · PubMed Central

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 62 references

Research works printed but not linked: 10

  1. Kim S, 2014, Mol Cancer Ther, 12
  2. Tripathy D, 2017, Paper presented at San Antonio Breast Cancer Symposium
  3. Tolaney SM, 2016, Paper presented at San Antonio Breast Cancer Symposium
  4. Martin M, 2017, Paper presented at San Antonio Breast Cancer Symposium
  5. Ciruelos E, 2017, Paper presented at San Antonio Breast Cancer Symposium
  6. Rugo HS, 2017, Paper presented at San Antonio Breast Cancer Symposium
  7. Lenihan C, 2016, Paper presented at San Antonio Breast Cancer Symposium
  8. Goetz M, 2017, Paper presented at San Antonio Breast Cancer Symposium
  9. Finn RS, 2017, Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study
  10. Hortobagyi GN, 2017, Paper presented at San Antonio Breast Cancer Symposium

Cited by

See all 316

Metadata

Authors
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S.
Affiliations
  • Department of Medical Oncology, Breast Cancer Unit, Institut Català d’Oncologia (ICO)-H.U.Bellvitge-IDIBELL, L’Hospitalet, Barcelona, Spain Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Dana-Farber Cancer Institute (US)
Corresponding author
Goel, Shom
Venue
Therapeutic Advances in Medical Oncology
Published
2018-01-01
Volume
10
Pages
1758835918786451-1758835918786451
ISSN
  • 1758-8340 (ISSN-L)
  • 1758-8359
OpenAlex
W2883670730
Cited by
316
References
62
Citations by year
2026: 15 · 2025: 29 · 2024: 24 · 2023: 46 · 2022: 40 · 2021: 56 · 2020: 64 · 2019: 38 · 2018: 4
FWCI
7.37
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Medical Oncology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
Funders
  • DF/HCC SPORE (Career Development Award)
  • Breast Cancer Alliance (Young Investigator Grant)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
CDK4/6 inhibitors, breast cancer, estrogen receptor-positive breast cancer, G1 cell cycle arrest, combination therapy, immune checkpoint inhibitors, endocrine therapy, progression-free survival, CDK4, CDK6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDK4/6 inhibition in breast cancer: current practice and future directions. https://app.cochat.ai/papers/10.1177/1758835918786451
The paper
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018). CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/1758835918786451

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.